Want to see IN:EPIGRAL full AI Analyst Report?
Top Page
Epigral Ltd
(EPIGRAL)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹1,075.00
▼(-7.57% Downside)
Action:Reiterated
Date:07/22/26
The score is driven primarily by solid profitability and a notably strengthened balance sheet, offset by weak and volatile cash generation (negative latest free cash flow and mixed cash conversion). Technical indicators are neutral-to-mixed (positive vs short-term averages but below the 200-day with negative MACD), while valuation appears reasonable with a low dividend yield.
Positive Factors
Healthy Profitability
Healthy operating and net margins indicate that Epigral retains meaningful profitability in its chemical business despite recent pressure. This earnings base can support reinvestment and resilience over the next several quarters, provided margins do not continue to deteriorate.
Negative Factors
Weak Cash Generation
Negative latest free cash flow and weak cash conversion create an earnings-quality concern because reported profits are not currently translating into equivalent cash generation. If sustained, this could restrict internally funded investment and increase reliance on working-capital or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthy Profitability
Healthy operating and net margins indicate that Epigral retains meaningful profitability in its chemical business despite recent pressure. This earnings base can support reinvestment and resilience over the next several quarters, provided margins do not continue to deteriorate.
Read all positive factors
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹43.76B
Dividend Yield0.51%
Average Volume (3M)3.53K
Price to Earnings (P/E)15.6
Beta (1Y)1.29
Revenue Growth4.81%
EPS Growth-37.93%
CountryIN
Employees1,135
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)62.82
Shares Outstanding43,141,340
10 Day Avg. Volume2,082
30 Day Avg. Volume3,532
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)62.1
Revenue Forecast (FY)₹27.01B
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epic...
How the Company Makes Money
EPIGRAL makes money mainly by selling chemical products to business customers (B2B) in the textile manufacturing ecosystem. Its core revenue streams typically include: (1) sales of textile auxiliaries and processing chemicals (e.g., pretreatment, ...
Epigral Ltd Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.26B | 24.95B | 25.50B | 18.94B | 21.69B | 15.50B |
| Gross Profit | 7.74B | 4.63B | 10.67B | 7.79B | 6.43B | 7.48B |
| EBITDA | 5.88B | 5.50B | 7.11B | 4.77B | 6.81B | 5.01B |
| Net Income | 2.71B | 3.32B | 3.58B | 1.96B | 3.53B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 35.05B | 31.52B | 27.94B | 24.32B | 21.24B |
| Cash, Cash Equivalents and Short-Term Investments | 50.20M | 54.60M | 965.00M | 31.83M | 142.40M | 250.85M |
| Total Debt | 0.00 | 5.72B | 5.93B | 9.64B | 8.79B | 9.93B |
| Total Liabilities | -22.21B | 12.84B | 12.48B | 15.40B | 13.63B | 13.98B |
| Stockholders Equity | 22.21B | 22.21B | 19.05B | 12.54B | 10.69B | 7.26B |
Cash Flow | ||||||
| Free Cash Flow | 316.30M | -65.30M | 2.46B | -7.90M | 2.10B | -1.72B |
| Operating Cash Flow | 2.67B | 3.88B | 4.41B | 3.98B | 6.26B | 2.84B |
| Investing Cash Flow | -1.73B | -3.55B | -2.62B | -4.01B | -4.37B | -4.55B |
| Financing Cash Flow | -980.80M | -457.90M | -1.64B | -75.98M | -2.00B | 1.95B |
Epigral Ltd Technical Analysis
Negative
1163.05
Price Trends
1129.95
Negative
1129.11
Negative
1107.91
Negative
Market Momentum
-37.66
Positive
25.58
Positive
3.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Negative. The current price of 1163.05 is above the 20-day moving average (MA) of 1107.11, above the 50-day MA of 1129.95, and above the 200-day MA of 1107.91, indicating a bearish trend. The MACD of -37.66 indicates Positive momentum. The RSI at 25.58 is Positive, neither overbought nor oversold. The STOCH value of 3.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹35.36B | 13.25 | ― | 2.24% | 8.62% | 20.79% | |
62 Neutral | ₹43.76B | 15.60 | ― | 0.51% | 4.81% | -37.93% | |
61 Neutral | ₹10.27B | 12.30 | ― | 0.37% | 13.23% | 22.22% | |
60 Neutral | ₹45.38B | 66.77 | ― | 2.93% | 7.07% | ― | |
58 Neutral | ₹12.79B | 24.74 | ― | 0.99% | 1.41% | 946.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹208.82B | 25.99 | ― | 0.50% | 8.20% | 29.06% |
* General Sector Average
IN:EPIGRAL
Epigral Ltd
983.40
-736.03
-42.81%
IN:DEEPAKNTR
Deepak Nitrite Limited
1,493.70
-339.72
-18.53%
IN:GUJALKALI
Gujarat Alkalies & Chemicals Ltd.
604.25
66.84
12.44%
IN:INDOAMIN
Indo Amines Limited
136.35
-1.99
-1.44%
IN:STYRENIX
Styrenix Performance Materials Ltd
2,052.50
-276.85
-11.89%
IN:VALIANTORG
Valiant Organics Limited
478.35
139.40
41.13%
Epigral Ltd Corporate Events
Epigral Files Q1 FY27 Earnings Call Transcript With Exchanges
Jul 30, 2026
Epigral Limited has submitted to the stock exchanges the official transcript of its Q1 FY27 results conference call, held on July 27, 2026, in compliance with disclosure norms under SEBI’s listing regulations. The filing is addressed to both...
Epigral schedules one-on-one meeting with VVD Asset Managers
Jul 30, 2026
Epigral Ltd has notified the stock exchanges that it will hold a one-on-one meeting with VVD Asset Managers in Ahmedabad on Monday, 3 August 2026, as part of its ongoing investor and analyst engagement activities. The company emphasized that only ...
Epigral Denies Role in Surge in Trading Volumes, Cites Market-Driven Factors
Jul 22, 2026
Epigral Ltd has responded to a query from the National Stock Exchange after a significant increase in trading volumes of its shares across exchanges. The company stated that it has already made all required disclosures relating to its operations a...
Exchange Seeks Clarification From Epigral After Trading Surge
Jul 21, 2026
The exchange has reported a significant increase in trading volumes for Epigral Ltd shares and has intervened to ensure investors have access to the most up to date information. In response to this unusual market activity, the exchange has formall...
Epigral Creates Wholly-Owned Chemical Subsidiary to Bolster Manufacturing Reach
Jul 7, 2026
Epigral Limited has incorporated a new wholly-owned subsidiary, Epigral Advanced Materials Limited, in India to expand its manufacturing footprint in chemicals. The unit, set up with a paid-up capital of Rs 1,00,000 and fully owned by Epigral, is ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.